Get the Stockscreener App
3.57
9.85%
0.32
After Hours:
3.48
-0.09
-2.52%
Whitehawk Therapeutics Inc stock is traded at $3.57, with a volume of 173.57K.
It is up +9.85% in the last 24 hours and up +31.73% over the past month.
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.
See More
Previous Close:
$3.25
Open:
$3.18
24h Volume:
173.57K
Relative Volume:
1.23
Market Cap:
$168.25M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+9.85%
1M Performance:
+31.73%
6M Performance:
+96.15%
1Y Performance:
+0.00%
1-Day Range:
$3.18
$3.59
1-Week Range:
$3.02
$3.59
52-Week Range:
$1.39
$3.7699
Whitehawk Therapeutics Inc Stock (WHWK) Company Profile
Name
Whitehawk Therapeutics Inc
Sector
Industry
Phone
551-321-2234
Address
2 HEADQUARTERS PLAZA, MORRISTOWN
Compare WHWK vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
WHWK
Whitehawk Therapeutics Inc
|
3.57 | 153.17M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Whitehawk Therapeutics Inc Stock (WHWK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-05-26 | Initiated | Oppenheimer | Outperform |
| Aug-27-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-21-24 | Downgrade | Jefferies | Buy → Hold |
| Aug-21-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-15-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jan-11-22 | Initiated | Jefferies | Buy |
| Oct-01-21 | Initiated | Cowen | Outperform |
| Sep-14-21 | Initiated | Ladenburg Thalmann | Buy |
| Sep-08-21 | Initiated | Piper Sandler | Overweight |
View All
Whitehawk Therapeutics Inc Stock (WHWK) Latest News
Aadi Bioscience Conference: Whitehawk CEO Details 3-Program ADC Pipeline, First Data Seen in 2027 - Defense World
Aug Closing: Can Whitehawk Therapeutics Inc reach resistance levels soonJuly 2025 Short Interest & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
Whitehawk Therapeutics : Corporate Presentation March 2026 - marketscreener.com
WHWK: Three differentiated ADCs in parallel, targeting broad cancers with best-in-class stability and safety - TradingView
Whitehawk Therapeutics to Participate in Upcoming Investor Conferences - ChartMill
Whitehawk Therapeutics (WHWK) Price Target Increased by 11.11% to 5.10 - Nasdaq
Aadi Bioscience Conference: CEO Spotlights Whitehawk ADC Pipeline, Cash Runway Through 2028 - Yahoo Finance
WHWK Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cancer drug developer Whitehawk joins Oppenheimer health conference - Stock Titan
Can Whitehawk Therapeutics Inc. (3350) stock sustain double digit ROEJuly 2025 Chart Watch & Low Risk Entry Point Guides - mfd.ru
Can Whitehawk Therapeutics Inc. (3350) stock reach $200 price targetMarket Sentiment Report & Daily Entry Point Trade Alerts - mfd.ru
How Whitehawk Therapeutics Inc. stock reacts to global recession fearsTrade Entry Summary & Fast Momentum Entry Tips - mfd.ru
Will Whitehawk Therapeutics Inc. outperform tech stocksJuly 2025 Volume & High Win Rate Trade Tips - mfd.ru
Is Whitehawk Therapeutics Inc.’s growth already priced in2025 Fundamental Recap & High Accuracy Investment Entry Signals - mfd.ru
Published on: 2026-02-13 19:37:08 - baoquankhu1.vn
Will Whitehawk Therapeutics Inc. stock deliver strong dividend growthChart Signals & Long-Term Capital Growth Strategies - mfd.ru
Is Whitehawk Therapeutics Inc. stock technically oversold2025 Major Catalysts & Reliable Price Breakout Alerts - mfd.ru
Oppenheimer Begins Coverage on Whitehawk Therapeutics (NASDAQ:WHWK) - Defense World
Oppenheimer initiates Whitehawk Therapeutics (WHWK) with Outperform Feb 2026 - Meyka
Oppenheimer Initiates Coverage on Whitehawk Therapeutics (NASDAQ:WHWK) - MarketBeat
Whitehawk Therapeutics (NASDAQ:WHWK) Trading 0.7% HigherStill a Buy? - MarketBeat
Retail Trends: Can FreightCar America Inc be recession proofJuly 2025 Market Mood & Low Risk Profit Maximizing Plans - baoquankhu1.vn
Aug Reactions: Will Whitehawk Therapeutics Inc outperform tech stocks2025 Price Action Summary & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Will Whitehawk Therapeutics Inc outperform the market in YEAR2025 Key Highlights & High Conviction Trade Alerts - baoquankhu1.vn
Investment Recap: Will Whitehawk Therapeutics Inc outperform the market in YEAR2025 Investor Takeaways & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Whitehawk Therapeutics (WHWK) price target increased by 125.00% to 4.59 - MSN
Support Test: Should I set a stop loss on Onfolio Holdings IncTake Profit & Free Safe Entry Trade Signal Reports - baoquankhu1.vn
Can Whitehawk Therapeutics Inc sustain its profitability2025 Pullback Review & Weekly Sector Rotation Insights - baoquankhu1.vn
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Shares Fly 27% But Investors Aren't Buying For Growth - simplywall.st
Whitehawk Therapeutics (WHWK) Price Target Increased by 125.00% to 4.59 - Nasdaq
Whitehawk Therapeutics (NASDAQ:WHWK) Stock Price Down 2.7%Here's What Happened - MarketBeat
Whitehawk Therapeutics (NASDAQ:WHWK) Stock Price Down 2.7% – Here’s What Happened - Defense World
Published on: 2026-01-10 19:11:09 - ulpravda.ru
Why Whitehawk Therapeutics Inc. stock is favored by top institutionsJuly 2025 Technicals & Reliable Trade Execution Plans - Улправда
Following a 26% decline over last year, recent gains may please Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) hedge funds owners - Sahm
Will Whitehawk Therapeutics Inc. stock continue upward momentumJuly 2025 Chart Watch & Verified Stock Trade Ideas - ulpravda.ru
Why Whitehawk Therapeutics Inc. stock attracts high net worth investorsWeekly Profit Summary & Free Expert Approved Momentum Trade Ideas - Улправда
How Whitehawk Therapeutics Inc. stock performs in rate cut cyclesPortfolio Growth Summary & Free Safe Entry Trade Signal Reports - ulpravda.ru
Will Whitehawk Therapeutics Inc. stock pay special dividendsEarnings Growth Summary & Weekly High Return Stock Opportunities - ulpravda.ru
Why institutional investors increase stakes in Whitehawk Therapeutics Inc. (3350) stockJuly 2025 EndofMonth & Community Trade Idea Sharing - Улправда
Whitehawk receives FDA clearance for PTK7-targeted cancer drug - Investing.com
Whitehawk Therapeutics Advances to Clinical Stage with IND Clearance for HWK-007 and Announces IND Submission for HWK-016 - The AI Journal
Published on: 2026-01-07 23:20:08 - Улправда
Can Whitehawk Therapeutics Inc. stock weather global recessionCandlestick Trading Patterns & Access Powerful Market Insights - Улправда
Free cash flow per share of Whitehawk Therapeutics, Inc. – DUS:3350 - TradingView — Track All Markets
Whitehawk Therapeutics, Inc.Common Stock (Nasdaq:WHWK) Stock Quote - FinancialContent
Whitehawk Therapeutics (NASDAQ:WHWK) Now Covered by Jones Trading - MarketBeat
Whitehawk Therapeutics (WHWK) Receives Buy Rating from Jones Tra - GuruFocus
Jones Trading initiates coverage on Whitehawk Therapeutics stock with Buy rating - Investing.com Canada
Published on: 2025-12-21 14:50:11 - Улправда
Analyzing Whitehawk Therapeutics (NASDAQ:WHWK) & Vaccinex (NASDAQ:VCNX) - Defense World
Whitehawk Therapeutics Inc Stock (WHWK) Financials Data
There is no financial data for Whitehawk Therapeutics Inc (WHWK). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):